Genetic and antigenic characterization of invasive endemic serogroup b neisseria meningitidis from ontario, Canada, in 2001-2010

Journal of Medical Microbiology

Volumn 62, Issue PART1, 2013, Pages 46-55

  Jamieson, Frances B ^a,b   Rawte, Prasad ^a   Deeks, Shelley L ^a,c   Zhou, Jianwei ^d   Law, Dennis K S ^d   Deng, Saul ^d   Tsang, Raymond S W ^d  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENICITY; ARTICLE; CANADA; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MOLECULAR CLONING; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CLUSTER ANALYSIS; ENDEMIC DISEASES; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; GENOTYPE; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; ONTARIO; SEROTYPING; TIME FACTORS;

EID: 84871178730     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.050369-0     Document Type: Article

References (69)

1. Abdillahi, H. & Poolman, J. T. (1987). Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 48, 367-371.
2. Al-Tawfiq, J. A., Clark, T. A. & Memish, Z. A. (2010). Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med 17 (Suppl.), 3-8.
3. Ashton, F. E. & Caugant, D. A. (2001). The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. Can J Microbiol 47, 283-289.
4. Ashton, F. E., Ryan, J. A., Borczyk, A., Caugant, D. A., Mancino, L. & Huang, D. (1991a). Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 29, 2489-2493.
5. Ashton, F. E., Mancino, L., Ryan, A. J., Poolman, J. T., Abdillahi, H. & Zollinger, W. D. (1991b). Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989. Can J Microbiol 37, 613-617.
6. Bambini, S., Muzzi, A., Olcen, P., Rappuoli, R., Pizza, M. & Comanducci, M. (2009). Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27, 2794-2803.
7. Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, O., Fredriksen, J. H., Halstensen, A., Holten, E., Lindbak, A. K., Nøkleby, H. & other authors (1991). Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096.
8. Brooks, R., Woods, C. W., Benjamin, D. K., Jr & Rosenstein, N. E. (2006). Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 43, 49-54.
9. Caugant, D. A. (1998). Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106, 505-525.
10. Chiou, C.-S., Liao, J.-C., Liao, T.-L., Li, C.-C., Chou, C.-Y., Chang, H.-L., Yao, S.-M. & Lee, Y.-S. (2006). Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis 6, 25.
11. Clarke, S. C., Diggle, M. A., Mölling, P., Unemo, M. & Olcén, P. (2003). Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Vaccine 21, 2468-2473.
12. de Filippis, I., Gopalan, V. & Huyen, Y. (2011). A web-based resource for the determination of PorA VR3 alleles of Neisseria meningitidis. Infect Gene Evol 11, 248-249.
13. de Moraes, J. C., Perkins, B. A., Camargo, M. C., Hidalgo, N. T., Barbosa, H. A., Sacchi, C. T., Landgraf, I. M., Gattas, V. L., Vasconcelos, H. G. & other authors (1992). Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074-1078.
14. Deeks, S. L., Kertesz, D., Ryan, A., Johnson, W. & Ashton, F. (1997). Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep 23, 121-125.
15. Feavers, I. M., Gray, S. J., Urwin, R., Russell, J. E., Bygraves, J. A., Kaczmarski, E. B. & Maiden, M. C. J. (1999). Multilocus sequence typing and antigen gene sequencing in the investigation of a meningococcal disease outbreak. J Clin Microbiol 37, 3883-3887.
16. Finne, J., Leinonen, M. & Mäkelä, P. H. (1983). Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 322, 355-357.
17. Francisco, A. P., Bugalho, M., Ramirez, M. & Carriço, J. A. (2009). Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach. BMC Bioinformatics 10, 152.
18. Frasch, C. E., Zollinger, W. D. & Poolman, J. T. (1985). Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7, 504-510.
19. Giuliana, M. M., Adu-Bobie, J., Caoanducci, M., Arico, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A. & other authors (2006). A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103, 10834-10839.
20. Hao, W., Ma, J. H., Warren, K., Tsang, R. S. W., Low, D. E., Jamieson, F. B. & Alexander, D. C. (2011). Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol Evol 3, 1406-1418.
21. Harrison, L. H., Shutt, K. A., Schmink, S. E., Marsh, J. W., Harcourt, B. H., Wang, X., Whitney, A. M., Stephens, D. S., Cohn, A. A. & other authors (2010). Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000-2005. J Infect Dis 201, 1208-1224.
22. Harrison, O. B., Brueggemann, A. B., Caugant, D. A., van der Ende, A., Frosch, M., Gray, S., Heuberger, S., Krizova, P., Olcen, P. & other authors (2011). Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology 157, 2181-2195.
23. Holmes, E. C., Urwin, R. & Maiden, M. C. (1999). The influence of recombination on the population structure and evolution of the human pathogen Neisseria meningitidis. Mol Biol Evol 16, 741-749.
24. Howitz, M., Krause, T. G., Simonsen, J. B., Hoffmann, S., Frisch, M., Nielsen, N. M., Robbins, J., Schneerson, R., Mølbak, K. & Miller, M. A. (2007). Lack of association between group B meningococcal disease and autoimmune disease. Clin Infect Dis 45, 1327-1334.
25. Johswich, K. O., Zhou, J., Law, D. K. S., St Michael, F., McCaw, S. E., Jamieson, F. B., Cox, A. D., Tsang, R. S. W. & Gray-Owen, S. D. (2012). Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis. Infect Immun 80, 2346-2353.
26. Joseph, B., Schneiker-Bekel, S., Schramm-Glück, A., Blom, J., Claus, H., Linke, B., Schwarz, R. F., Becker, A., Goesmann, A. & other authors (2010). Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J Bacteriol 192, 5363-5377.
27. Kertesz, D., Coulthart, M., Ryan, A., Johnson, W. & Ashton, F. (1998). Serogroup B electrophoresis type 15 Neisseria meningitidis. Can J Infect Dis Med Microbiol 177, 1754-1757.
28. Ladhani, S. N., Flood, J. S., Ramsay, M. E., Campbell, H., Gray, S. J., Kaczmarski, E. B., Mallard, R. H., Guiver, M., Newbold, L. S. & Borrow, R. (2012). Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 30, 3710-3716.
29. Law, D. K. S., Lorange, M., Ringuette, L., Dion, R., Giguère, M., Henderson, A. M., Stoltz, J., Zollinger, W. D., De Wals, P. & Tsang, R. S. W. (2006). Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 44, 2743-2749.
30. Lo, H., Tang, C. M. & Exley, R. M. (2009). Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 9, 418-427.
31. Lucidarme, J., Comanducci, M., Findlow, J., Gray, S. J., Kaczmarski, E. B., Guiver, M., Kugelberg, E., Vallely, P. J., Oster, P. & other authors (2009). Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 47, 3577-3585.
32. Lucidarme, J., Comanducci, M., Findlow, J., Gray, S. J., Kaczmarski, E. B., Guiver, M., Vallely, P. J., Oster, P., Pizza, M. & other authors (2010). Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 17, 919-929.
33. Lucidarme, J., Tan, L., Exley, R. M., Findlow, J., Borrow, R. & Tang, C. M. (2011). Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 18, 1002-1014.
34. Maiden, M. C. J. & Urwin, R. (2006). Population dynamics of bacterial pathogens. In Evolution of Microbial Pathogens, pp. 35-53. Edited by H. S. Seifert. Washington, DC: American Society for Microbiology.
35. Maiden, M. C. J., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Urwin, R., Zhang, Q., Zhou, J., Zurth, K. & other authors (1998). Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95, 3140-3145.
36. Marri, P. R., Paniscus, M., Weyand, N. J., Rendón, M. A., Calton, C. M., Hernández, D. R., Higashi, D. L., Sodergren, E., Weinstock, G. M. & other authors (2010). Genome sequencing reveals widespread virulence gene exchange among human Neisseria species. PLoS ONE 5, e11835.
37. Martin, D. R., Ruijne, N., McCallum, L., O'Hallahan, J. & Oster, P. (2006). The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13, 486-491.
38. Mayer, L. W., Reeves, M. W., Al-Hamdan, N., Sacchi, C. T., Taha, M. K., Ajello, G. W., Schmink, S. E., Noble, C. A., Tondella, M. L. & other authors (2002). Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 185, 1596-1605.
39. Navarro, C., Deeks, S. L., Medagha, A. & Tsang, R. S. W. (2007). Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 33, 1-15.
40. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S. & Martin, D. (2005). MeNZBTM: a safe and highly immunogenic tailormade vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191-2196.
41. Patrick, D. M., Champagne, S., Goh, S. H., Arsenault, G., Thomas, E., Shaw, C., Rahim, T., Taha, F., Bigham, M. & other authors (2003). Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis 37, 1183-1188.
42. Pillai, S., Howell, A., Alexander, K., Bentley, B. E., Jiang, H. Q., Ambrose, K., Zhu, D. & Zlotnick, G. (2005). Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23, 2206-2209.
43. Pollard, A. J., Tam, T. W. S. & National Advisory Committee on Immunisation (NACI) (2001). An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 27, 2-36.
44. Richmond, P. C., Marshall, H. S., Nissen, M. D., Jiang, Q., Jansen, K. U., Garcés-Sánchez, M., Martinón-Torres, F., Beeslaar, J., Szenborn, L. & other authors (2012). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, singleblind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12, 597-607.
45. Riou, J. Y. & Guibourdenche, M. (1992). Laboratory Methods, Neisseria and Branhamella. Paris, France: Institut Pasteur.
46. Robbins, J. B., Schneerson, R., Xie, G., Hanson, L. A. & Miller, M. A. (2011). Capsular polysaccharide vaccine for group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2. Proc Natl Acad Sci U S A 108, 17871-17875.
47. Rosenstein, N. E., Perkins, B. A., Stephens, D. S., Popovic, T. & Hughes, J. M. (2001). Meningococcal disease. N Engl J Med 344, 1378-1388.
48. Sacchi, C. T., Lemos, A. P., Brandt, M. E., Whitney, A. M., Melles, C. E. A., Solari, C. A., Frasch, C. E. & Mayer, L. W. (1998). Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5, 845-855.
49. Santolaya, M. E., O'Ryan, M. L., Valenzuela, M. T., Prado, V., Vergara, R., Muñoz, A., Toneatto, D., Granña, G., Wang, H. & other authors (2012). Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379, 617-624.
50. Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R. & Terry, M. H. (1991). Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14, 195-207. discussion 208-210.
51. Squires, S. G., Pelletier, L., Mungai, M., Tsang, R., Collins, F. & Stoltz, J. (2000). Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 26, 177-182.
52. Squires, S. G., Deeks, S. L. & Tsang, R. S. W. (2004). Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 30, 17-28.
53. Takahashi, H., Kuroki, T., Watanabe, Y., Tanaka, H., Inouye, H., Yamai, S. & Watanabe, H. (2004). Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Med Microbiol 53, 657-662.
54. Tsang, R. S. W., Squires, S. G., Zollinger, W. D. & Ashton, F. E. (2002). Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis Med Microbiol 13, 391-396.
55. Tsang, R. S. W., Kiefer, L., Law, D. K. S., Stoltz, J., Shahin, R., Brown, S. & Jamieson, F. (2003). Outbreak of serogroup C meningococcaldisease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. J Clin Microbiol 41, 4411-4414.
56. Tsang, R. S. W., Tsai, C. M., Zhu, P., Ringuette, L., Lorange, M. & Law, D. K. S. (2004). Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada. J Clin Microbiol 42, 1460-1465.
57. Tsang, R. S. W., Law, D. K. S., Henderson, A. M., Blake, M. L. & Stoltz, J. (2006). Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J Infect Dis 194, 1791-1792 author reply 1792-1793.
58. Tsang, R. S. W., Henderson, A. M., Cameron, M. L., Tyler, S. D., Tyson, S., Law, D. K. S., Stoltz, J. & Zollinger, W. D. (2007). Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 45, 1753-1758.
59. Tsang, R. S. W., Tsai, C. M., Henderson, A. M., Tyler, S., Law, D. K. S., Zollinger, W. & Jamieson, F. (2008). Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135. Can J Microbiol 54, 229-234.
60. Tsang, R. S. W., Lefebvre, B., Jamieson, F. B., Gilca, R., Deeks, S. L. & Zhou, J. (2012). Identification and proposal of a potentially new clonal complex that is a common cause of MenB disease in central and eastern Canada. Can J Microbiol 58, 1236-1240.
61. Tyrrell, G. J., Chui, L., Johnson, M., Chang, N., Rennie, R. P., Talbot, J. A. & Edmonton Meningococcal Study Group (2002). Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 8, 519-521.
62. Vedros, N. A. (1987). Development of meningococcal serogroups. In Evolution of Meningococcal Disease, pp. 33-37. Edited by N. A. Vedros. Boca Raton, FL: CRC Press.
63. Vogel, U., Szczepanowski, R., Claus, H., Jünemann, S., Prior, K. & Harmsen, D. (2012). Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information. J Clin Microbiol 50, 1889-1894.
64. Wang, J. F., Caugant, D. A., Morelli, G., Koumaré, B. & Achtman, M. (1993). Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 167, 1320-1329.
65. Warshawsky, B., Desai, S. & Langley, J. (2009). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement. Can Commun Dis Rep 36, 1-40.
66. Watkins, K. M., Deeks, S. L., Medqaglia, A. & Tsang, R. S. W. (2006). Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep 32, 97-107.
67. Yang, L., Shao, Z., Zhang, X., Xu, L., Peng, J., Xu, X., Liang, X., Qi, Y. & Jin, Q. (2008). Genotypic characterization of Neisseria meningitidis serogroup B strains circulating in China. J Infect 56, 211-218.
68. Yazdankhah, S. P., Kriz, P., Tzanakaki, G., Kremastinou, J., Kalmusova, J., Musilek, M., Alvestad, T., Jolley, K. A., Wilson, D. J. & other authors (2004). Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 42, 5146-5153.
69. Zhou, J., Lefebvre, B., Deng, S., Gilca, R., Deceuninck, G., Law, D. K. S., De Wals, P. & Tsang, R. S. W. (2012). Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 50, 1545-1551.